Vikram Purohit is an Equity Analyst & Vice President at Morgan Stanley and covers SMID-cap biotechnology stocks. He previously was an associate in Morgan Stanley’s Biotechnology equity research group, where he supported the coverage of large and SMID-cap biotech stocks. Prior to his time in equity research, Vikram worked in healthcare investment banking at Credit Suisse and in healthcare consulting at Booz Allen Hamilton. Vikram has a BS in Biochemistry & Molecular Biology from the University of Florida and an MBA from Columbia Business School.